• Loading stock data…

Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)

[#item_full_content]

Print Friendly, PDF & Email
Spread the word